Articles About Medtech

This Company Is Clearing the Way for Next-Gen Heart treatments

0 | By Michael A. Robinson

When it comes to keeping healthy, calcium can be both friend and foe.

Like we constantly hear from health officials, our bodies need it to reinforce the structures of our teeth and bones, and it’s a part of keeping our body chemistry working efficiently.

But there’s also a downside to calcium; it can impede the circulatory system, and get in the way of some of the miraculous new high-tech procedures that can offer an alternative to open-heart surgery.

I’ve already found a medical innovator that is solving this problem. Not only do they have an $8 billion market to focus on, but their shares are beating the S&P 500 by 531%, or five times over.

And I’d like to show you why I see it going even further up…

Here’s The Technology Battling America’s Invisible Health Crisis

0 | By Michael A. Robinson

With Covid hospitalizations and deaths dramatically on the rise, it’s easy to overlook another major healthcare crisis confronting America.

And yet, it’s one that could affect as many as 120 million of us and pose profound long-term medical issues.

Ironically, the Covid binge eating of “comfort food” we’ve seen over the last 18 months may add to the new level of concern.

Of course, I’m talking about the nation’s obesity crisis.

There’s a silent health crisis A recent report by the American Obesity Association says 42% of Americans are obese.

No wonder a federal panel recently recommended lowering the age to begin screening for diabetes, which is closely tied to being overweight, down to 35.

To me, the two reports together mean that a life sciences firm with a strong diabetes hook will be in high demand.

With that in mind, I want to reveal a company taking on the challenge of this $72.8 billion sector with a leader that is beating the overall market by nearly fourfold…

This Med Tech Innovator Just Doubled, And It Can Do It Again

0 | By Michael A. Robinson

When we last talked last Friday, I showed you how a software executive founded biotech company Veeva Systems Inc. (VEEV) and turned his expertise in cloud software into a 1,253% gain for investors.

That’s over the last seven years, mind you. Enough to turn $25,000 into $338,250 and up to $1.35 million in the next four years.

Here’s the thing. If you’re a “set-and-forget” investor happy to match the S&P 500, you’ve come to the wrong place.

We’re here to crush the market with the foremost innovative tech leaders

Over the seven years I’m talking about, the S&P 500 gained a very respectable 128%.

Not bad. Unless you compare it to VEEV.

Veeva beat it by a staggering 879%.

This Visionary Tech Leader Can Make You a Lot of Money

0 | By Michael A. Robinson

The trial of Elizabeth Holmes of the failed MedTech startup Theranos began this week. We all know the story, but the biggest takeaway for tech investors is that Holmes founded Theranos at a time when venture capitalists were throwing money at any young tech founder who used the word “disrupt” a lot.

Leadership is crucial in the tech world, but wearing turtlenecks or referring to your enterprise as a “state of consciousness” has little to do with it.

I’ve seen our fair share of Elizabeth Holmes’ and Adam Neumann’s, but I’ve also seen real visionary leaders with powerful ideas and solid management skills that can turn ordinary investors into millionaires- leaders like Peter Gassner.

Had you bought the stock of Gassner’s biotech company at the beginning of Aug. 2014, you would have made a 1,253% return. That’s enough to turn $25,000 into $338,250 in just seven years.

Today, in the first of two parts, I’m going to show you why there are two more doubles ahead for a total of $1.35 million…

A 263% Growth Spurt Is Just the Beginning for This MedTech Trailblazer

0 | By Michael A. Robinson

We recently passed the one-year anniversary of a bold call I made about a MedTech leader that was inspired by a reality show.

On June 20, 2020 this pioneer in aesthetic medicine was still flying under Wall Street’s radar.

And that’s just fine with us. As savvy tech investors we know all too well that by beating the so-called “pros” to the punch, we set ourselves up to really crush the market.

Since then, the S&P 500 has risen 39.8% in a historic run, which is nice and all, but the firm I recommended last June smoked those returns by a stunning 560.8%.

As a major disruptor in the plastic surgery market, this firm’s stock is way ahead of my forecast and has actually gained 263% for a nearly four-fold increase in 13 months.

Even with this much growth, I see plenty of upside ahead.

Let me show you why there’s at least another double in the making…

This Franchise’s Stock Will Double While Riding This Unstoppable Healthcare Trend

0 | By Michael A. Robinson

I can say from personal experience that home health care for seniors and hospice services are a godsend to millions.

And not just because there’s a lot of money up for grabs. More on that in a moment.

Here’s the thing. I recently mentioned that my father passed away after a battle with congestive heart failure.

We were fortunate to be able to find a crackerjack health team to work with him in his Virginia home. In fact, they were with him when he passed away on May 27.

So, I know first-hand that these services can bring big emotional payoffs.

More than just an essential service, home healthcare is also a very lucrative field that continues to grow alongside a national trend.

Analysts say the home health care market to be worth $225 billion by 2024.

Today, I’m going to reveal a leader in this field whose stock could double in less than three years…

This Medtech Leader Is Coming Back From Covid

0 | By Michael A. Robinson

After all the trouble that Covid caused for the med-tech sector, one innovative leader is on its way to coming back better than ever. Nothing proves that better than their recent beat-and-raise quarter.

For the March quarter, the firm earned $3.52 per share, up 31% and crushing forecasts. Analysts had expected per-share profits of $2.64, or 25 less than the actual results.

With the Covid recovery underway, the company raised guidance for the full year. It now expects growth in robotic procedures of as much as 26% for all of 2021, compared with Wall Street’s 18% forecast.

This medtech firm specializes in sophisticated gear for robotic surgeries, during Covid, a huge amount of the $1.1 trillion US healthcare market was focused on treating coronavirus cases.

That meant that elective surgeries for the fiscal year ended in March were pretty much out the window, and the companies that target them fell out of favor.

But now, all of that is in the rearview mirror.

Instead, this company just reminded tech investors of the great value proposition here by easily beating Wall Street forecasts.

With that news as a spark, the stock jumped 9.9% in a single session on May 21. It’s now back in a nice uptrend.

Let me show you why this good news means this company is just getting started…

When This Company Reports Earnings, We’ll Win No Matter How It Goes

0 | By Michael A. Robinson

Coming up next month, we’re about to have a golden opportunity to see a key aspect of my investing philosophy in action.

Just because Wall Street might panic after catching a scrap of bad news doesn’t change the fundamental outlook of an investment.

There’s no better time to keep than in mind than right now, with a firm I’ve been keeping my eye on about to report earnings.

That report is giving us a chance to repeat a big win that I called back on July 26 of 2019, when I brought you a medtech leader that I still believed in, even when their stock had just gotten throttled.

Bear in mind, I made that call the day after the company lost more than 25% of its value in a single session. I still believed in them then, and I was right. Since then, they’ve offered a potential 191% return.

Over the years, I’ve found that out-of-favor tech stocks can present huge buying opportunities because, after 37 years of experience in Silicon Valley, I know the lay of the land

And now, with their earnings report coming up next month, let me show you five very important reasons why I still believe in this company just as much as ever

Everyone Is Wrong Once Again About Teledoc – Here’s How We’re Turning Those Mistakes Into Our Gains

0 | By Michael A. Robinson

On August 25, 2020, I said that there was a fire sale you as a savvy tech investor could take advantage of with Teledoc Health Inc. (TDOC).

Wall Street analysts were worried about Teledoc buying Livongo Health Inc. (LVGO) and the $18.5 billion price tag. But I know this was a big move that would add to TDOC’s lead in the shift to telemedicine.

Livongo makes devices that allow healthcare providers to remotely monitor health metrics such as blood pressure, blood sugar, weight, even behavioral health. Together they allow physicians and nurses to speak to patients remotely while having the most up-to-date information on their health.

I made it clear back then that I expected Teledoc Health Inc. (TDOC) to bounce back and beat the market.

From the day shares hit a bottom on November 10 to its recent high on February 19, TDOC zoomed some 69.6%.

Over that period, it crushed the S&P 500 by a stunning 640%.

Now, history is repeating itself, and this massive profit opportunity is coming back around. The stock is grossly oversold once again, and I see a similar setup in the making as the firm disrupts the $1.3 trillion medical market.

Here’s the thing.

According to a survey from The Harris Poll, 65% of consumers surveyed plan to use telehealth services more often after the pandemic, putting paid to Wall Street’s ridiculous notion that we’re just itching to go back to the doctor’s office.

This is still a move well worth making.

Let me show you what’s really going on and how you can clean up from Wall Street’s mistake…

Wall Street is Counting Out the Biggest Breakthrough in Medicine – Here’s How to Make Their Mistake into Your Gain

0 | By Michael A. Robinson

When Wall Street overreacts and goes right, you can make a fortune by avoiding the noise and going in the opposite direction.

In the latest edition of wild overreactions, Cathie Wood, the top-notch ETF manager of Ark Investment Management, received some flak from The Wall Street Journal.

I’ll have more on that in just a bit and why it is totally off the mark.

But make no mistake. Wood has an uncanny eye for finding breakout stocks with a market-beating track record to prove it.

One particular feather in Wood’s cap is an ETF that she runs focusing on the cutting-edge field of genomics, a tech that basically didn’t exist just a decade ago.

Without genomics, we wouldn’t have been able to understand the structure of the coronavirus. Not only that, but the first two vaccines approved both relied on a hot new segment of genomics.

And this is an industry that is projected to multiply from $18.85 billion in 2019 to $82.60 billion in 2027, according to Fortune Business Insights. That’s more than 300% growth in less than a decade.

I’ll give you more details in a moment. But first, I want to point out the sizzling returns that Wood has amassed.

Over roughly the past year, Wood’s fund beat the market by a stunning 471%.

Let me show you why this play is just getting started…